Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Score 00–0
- Score 11–1
- Score 22–2
- Score ≥33–5
The Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival calculator is designed for bedside predicting transplantation survival of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) based on five pre-transplant risk factors in clinical practice. The resulting score directly guides clinician decision-making regarding initiating.
Clinical Guidelines & Evidence
Predicts transplantation survival of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) based on five pre-transplant risk factors.
Clinical Indication
The Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival is indicated for bedside clinical practice to support Predicts transplantation survival of AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) based on five pre-transplant risk factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention. Clinical exclusion: Reduced-intensity conditioning, syngeneic, and cord blood transplants were excluded from the original study..
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Only busulfan and TBI-based myeloablative conditioning regimens were studied in the original validation..
Score = disease_group_points + cytogenetics_points + hla_match_points + circulating_blasts_points + karnofsky_points. Total score ranges from 0-5 points with lower scores indicating better prognosis.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| disease_group | string | Yes | Disease status at time of transplantation |
| cytogenetics | string | Yes | Cytogenetic risk category prior to HSCT |
| hla_match_group | string | Yes | HLA matching status between donor and recipient |
| circulating_blasts | string | Yes | Presence of circulating blasts at time of transplantation |
| karnofsky_lansky_scale | string | Yes | Karnofsky (adults) or Lansky (pediatric) performance status scale |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Score 0 | Excellent prognosis |
| 1–1 | Score 1 | Good prognosis |
| 2–2 | Score 2 | Intermediate prognosis |
| 3–5 | Score ≥3 | Poor prognosis |
Evidence-Based References (EBM)
- Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730-8. doi: 10.1200/JCO.2010.28.8852.DOI: 10.1200/JCO.2010.28.8852
- Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, et al. A phase 3 randomized study of 5-azacytidine vs physicians' choice as maintenance therapy for patients with AML in first remission after intensive chemotherapy ineligible for stem cell transplantation. Blood. 2013;121(24):4906-14.
- Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51(4):610-1.
- Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579-90. doi: 10.1038/nrclinonc.2012.150.DOI: 10.1038/nrclinonc.2012.150